Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Podcasts

Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: major trends and deals from the recent J.P. Morgan meeting, the impact of the US Inflation Reduction Act, the pricing of Alzheimer’s drug Leqembi and five blockbusters set to lose exclusivity this year.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.

Vision Possible: Why Eyestem Is 'Bullish' About Its Dry AMD Candidate

Eyestem founder and CEO talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.

Vaxxinity CEO On Lecanemab Challenger, Migraine Buster And Lipid-Lowering Vaccine

Among Vaxxinity’s immunotherapeutic vaccine candidates are one for Alzheimer’s that shows a 50% reduction in cognitive decline, another that shows superior durability than Pfizer and Moderna’s COVID-19 vaccines and one that could prevent migraines. Vaxxinity CEO speaks to Scrip about these and more in this interview

See All

ABOUT

Pharma Intelligence podcasts discuss key ideas and insights affecting biopharma and medtech, brought to you by our global team of editors. Listen on-demand to our perspectives on the latest industry developments.

FIND ALL PHARMA INTELLIGENCE PODCASTS ON:

MORE PODCASTS

UsernamePublicRestriction

Register